Clinical Presentation of invasive pneumococcal disease in Spain in the era of heptavalent conjugate vaccine

Pediatric Infectious Disease Journal

Volumn 31, Issue 2, 2012, Pages 124-128

  De Sevilla, Maria F ^a   García García, Juan José ^a   Esteva, Cristina ^a   Moraga, Fernando ^b   Hernańdez, Sergi ^c   Selva, Laura ^a   Coll, Francisco ^b   Ciruela, Pilar ^c   Planes, Ana Maria ^b   Codina, Gemma ^b   Salleras, Luis ^d,e   Jordan, Iolanda ^a   Domínguez, Angela ^d,e   Muñoz Almagro, Carmen ^a  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c GENERALITAT DE CATALUNYA   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

MLST; Pneumococcal conjugate vaccine; Pneumonia; Serotype; Streptococcus pneumoniae

Indexed keywords

PENICILLIN G; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; CLINICAL FEATURE; DNA ISOLATION; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEROTYPE; SPAIN; STREPTOCOCCUS PNEUMONIAE; TERTIARY HEALTH CARE;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; MENINGITIS, PNEUMOCOCCAL; MICROBIAL SENSITIVITY TESTS; MOLECULAR TYPING; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDIES; SEROTYPING; SPAIN; STREPTOCOCCUS PNEUMONIAE;

EID: 84858159852     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318241d09e     Document Type: Article

References (27)

1. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893-902.
2. Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part 1. Clin Infect Dis. 2000;30:100-121. (Pubitemid 30067069)
3. Black S, Shinefield H, Baxter R, et al. Postlicensure surveillance for pneumococcal disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J. 2004;23:485-489. (Pubitemid 38802290)
4. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746. (Pubitemid 36514704)
5. Muñoz-Almagro C, Jordan I, Gene A, et al. Emergence of invasive pneumococcal disease caused by non-vaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46:174-182. (Pubitemid 351269154)
6. Hausdorff WP, Bryant J, Kloek C, et al. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis. 2000;30:122-140. (Pubitemid 30067070)
7. Muñoz-Almagro C, Gala S, et al. DNA bacterial load in children and adolescents with pneumococcal pneumonia and empyema. Eur J Clin Microbiol Infect Dis. 2011;30:327-335.
8. Azzari C, Moriondo M, Indolfi G, et al. Molecular detection methods and serotyping performed directly on clinical samples improve diagnostic sensitivity and reveal increased incidence of invasive disease by Streptococcus pneumoniae in Italian children. J Med Microbiol. 2008;57:1205-1212.
9. Corless CE, Guiver M, Borrow R, et al. Simultaneous detection of Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae in suspected cases of meningitis and septicemia using real-time PCR. J Clin Microbiol. 2001;39:1553-1558. (Pubitemid 32275465)
10. Van Gastel E, Bruynseels P, Verstrepen W, et al. Evaluation of a real-time polymerase chain reaction assay for the diagnosis of pneumococcal and meningococcal meningitis in a tertiary care hospital. Eur J Clin Microbiol Infect Dis. 2007;26:651-653. (Pubitemid 47301396)
11. Lahti E, Mertsola J, Kontiokari T, et al. Pneumolysin polymerase chain reaction for diagnosis of pneumococcal pneumonia and empyema in children. Eur J Clin Microbiol Infect Dis. 2006;25:783-789. (Pubitemid 44786654)
12. Picazo J, Ruiz-Contreras J, Casado-Flores J, et al. Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar. Clin Vaccine Immunol. 2011;18:89 -94.
13. Web de l'Estadística Oficial de Catalunya. Institut d'Estadística de Catalunya. Available at: http://www.idescat.net. Accessed August 11, 2010.
14. National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing (2008): Eighteenth Informational Supplement. Wayne, PA: Clinical and Laboratory Standard Institute; 2008. CLSI document M100-S18 (ISBN 1-5-56238-653-0).
15. Fenoll A, Jado I, Vicioso D, et al. Dot blot assay for the serotyping of pneumococci. J Clin Microbiol. 1997;35:764-766. (Pubitemid 27083879)
16. Tarragó D, Fenoll A, Sánchez-Tatay D, et al. Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time PCR. Clin Microbiol Infect. 2008;14:828-834.
17. Enright MC, Spratt BG. A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology. 1998;144:3049-3060. (Pubitemid 28515583)
18. Feil EJ, Li BC, Aanensen DM, et al. eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J Bacteriol. 2004;186:1518-1530. (Pubitemid 38248742)
19. American Academy of Pediatrics, Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106:362-366.
20. Dagan R, Shriker O, Hazan I, et al. Prospective study to determine clinical relevance of detection of pneumococcal DNA in sera of children by PCR. J Clin Microbiol. 1998;36:669-673. (Pubitemid 28093247)
21. Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics. 2010;125:429-436.
22. Obando I, Muñoz-Almagro C, Arroyo LA, et al. Pediatric parapneumonic empyema, Spain. Emerg Infect Dis. 2008;14:1390-1397.
23. Winther TN, Kristensen TD, Kaltoft MS, et al. Invasive pneumococcal disease in Danish children, 1996-2007, prior to the introduction of heptavalent pneumococcal conjugate vaccine. Acta Pediatr. 2009;98:328-331.
24. Byington CL, Korgenski K, Daly J, et al. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J. 2006;25:250 -254.
25. Robinson K, Baughman W, Rothrock G, et al. Epidemiology of Streptococcus pneumoniae infections in the U.S., 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285:1729 -1735.
26. Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. Morb Mortal Wkly Rep. 2005;54:893- 897.
27. Muñoz-Almagro C, Selva L, Sanchez CJ, et al. PsrP, a protective pneumococcal antigen, is highly prevalent in children with pneumonia and is strongly associated with clonal type. Clin Vaccine Immunol. 2010;17:1672-1678.